Validation of a Questionnaire to Identify Respiratory Tract Infections in Children With Sickle Cell Disease

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Aliva De ◽  
Chika V. Anekwe ◽  
Meyer Kattan ◽  
Yujing Yao ◽  
Zhezhen Jin ◽  
...  
Toxins ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 157
Author(s):  
Joyce Gonzales ◽  
Trinad Chakraborty ◽  
Maritza Romero ◽  
Mobarak Abu Mraheil ◽  
Abdullah Kutlar ◽  
...  

Sickle cell disease (SCD) is one of the most common autosomal recessive disorders in the world. Due to functional asplenia, a dysfunctional antibody response, antibiotic drug resistance and poor response to immunization, SCD patients have impaired immunity. A leading cause of hospitalization and death in SCD patients is the acute chest syndrome (ACS). This complication is especially manifested upon infection of SCD patients with Streptococcus pneumoniae (Spn)—a facultative anaerobic Gram-positive bacterium that causes lower respiratory tract infections. Spn has developed increased rates of antibiotics resistance and is particularly virulent in SCD patients. The primary defense against Spn is the generation of reactive oxygen species (ROS) during the oxidative burst of neutrophils and macrophages. Paradoxically, Spn itself produces high levels of the ROS hydrogen peroxide (H2O2) as a virulence strategy. Apart from H2O2, Spn also secretes another virulence factor, i.e., the pore-forming exotoxin pneumolysin (PLY), a potent mediator of lung injury in patients with pneumonia in general and particularly in those with SCD. PLY is released early on in infection either by autolysis or bacterial lysis following the treatment with antibiotics and has a broad range of biological activities. This review will discuss recent findings on the role of pneumococci in ACS pathogenesis and on strategies to counteract the devastating effects of its virulence factors on the lungs in SCD patients.


2021 ◽  
Vol 11 (9) ◽  
pp. 870
Author(s):  
Pia Proske ◽  
Laura Distelmaier ◽  
Carmen Aramayo-Singelmann ◽  
Nikolaos Koliastas ◽  
Antonella Iannaccone ◽  
...  

Background: This monocentric study conducted at the University Hospital of Essen aims to describe maternal and fetal/neonatal outcomes in sickle cell disease (SCD) documented between 1996 to 2021 (N = 53), reflecting the largest monocentric analysis carried out in Germany. Methods/Results: 46 pregnancies in 22 patients were followed. None of the patients died. In total, 35% (11/31) of pregnancies were preterm. 15 pregnancies in eight patients were conceived on hydroxycarbamide (HC), of which nine had a successful outcome and three were terminated prematurely. There was no difference regarding the rate of spontaneous abortions in patients receiving HC compared to HC-naive patients prior to conception. In patients other than HbS/C disease, pregnancies were complicated by vaso-occlusive crises (VOCs)/acute pain crises (APCs) (96%, 23/24); acute chest syndrome (ACS) (13%, 3/24), transfusion demand (79%, 19/24), urinary tract infections (UTIs) (42%, 10/24) and thromboembolic events (8%, 2/24). In HbS/C patients complications included: VOCs/APCs (43%, 3/7; ACS: 14%, 1/7), transfusion demand (14%, 1/7), and UTIs (14%, 1/7). Independent of preterm deliveries, a significant difference with respect to neonatal growth in favor of neonates from HbS/C mothers was observed. Conclusion: Our data support the results of previous studies, highlighting the high rate of maternal and fetal/neonatal complications in pregnant SCD patients.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 2580-2580
Author(s):  
Mário Angelo Claudino ◽  
Carla Fernanda Franco-Penteado ◽  
Marcus A.F. Corat ◽  
Ana Paula Gimenes ◽  
Kleber Yotsumoto Fertrin ◽  
...  

Abstract Abstract 2580 Poster Board II-557 Genitourinary infection and urinary retention have been related to impaired urinary concentrating ability and altered urinary volume in sickle cell disease (SCD) patients. This condition may be associated with changes in the detrusor smooth muscle (DSM) reactivity. Berkeley transgenic SCD mice display several clinical manifestations similar to those seen in humans, but no studies assessing the alterations of DSM reactivity in SCD mice have been performed. DSM contractions are a consequence of the activation of muscarinic receptors that promote stimulation of phospholipase C, with increased formation of inositol trisphosphate and diacylglycerol to release calcium (Ca2+) from intracellular stores, leading to bladder emptying. The Ca2+-independent RhoA/Rho-kinase pathway is also involved in the regulation of bladder smooth muscle tone by alteration of the sensitivity of contractile proteins for Ca2+. Changes in the contraction mechanisms of DSM may contribute to bladder dysfunction. The aim of this study was to evaluate the contractile mechanisms of isolated DSM of transgenic SCD mouse. SCD (SS) and C57BL/6 (CTL) mice tissues were removed and mounted in 10ml organ baths containing Krebs solution at 37°C and continuously bubbled with a mixture of 95%O2:5%CO2 (pH 7.4). Tissues were stretched to a resting tension of 10 mN and allowed to equilibrate for 60 minutes. Changes in isometric force were recorded using a PowerLab400 Data Acquisition System. Cumulative concentration-response curves to muscarinic agonist carbachol (CCh; 0.01–100 μM) were obtained in the absence and presence of the Rho-kinase inhibitor Y-27632 (1–10 μM). Cumulative concentration-response curves were constructed to hyperpolarizing solution, potassium chloride (KCl; 1–300 mM) and calcium chloride (CaCl2; 0.01–100 mM). Frequency-response curves for electrical field stimulation (EFS; 1–32 Hz) were obtained in strips in the absence and presence of non-selective muscarinic antagonist atropine (1 μM) or purinergic receptor antagonist suramin (100 μM). Cumulative addition of the CCh produced concentration-dependent contractile responses in DSM, although the potency (pEC50) did not change in SS mice (5.80±0.02) compared with CTL mice (5.69±0.05). In contrast, the maximal response (Emax) was significantly reduced in SS mice (4.20±0.42mN) compared with CTL mice (9.96±1.77mN). In addition, the pEC50 and Emax elicited by CCh were reduced in the presence of Y-27632; however, no change was observed among all group studies. Cumulative addition of the KCl produced concentration-dependent contraction in DSM, and both pEC50 (0.98±0.08) and Emax (7.63±1.03mN) were significantly reduced in SS mice, compared with CTL mice (1.24±0.07; 11.24±0.84mN, respectively). CaCl2 produced concentration-dependent contractile responses, the pEC50 did not change in SS mice (2.00±0.06); however, the Emax was significantly reduced (10.1±0.25mN) when compared to CTL mice (1.92±0.05; 17.8±2.3mN). EFS-induced contractions in DSM of SS mice were decreased at significantly higher frequencies than compared to CTL mice. In addition, EFS-induced contractions in DSM were significantly decreased in the presence of atropine and suramin in both SS mice and CTL mice, but no change was observed among all group studies. Our study shows that SS mice exhibit impaired contractile responses to muscarinic agonist, KCl, CaCl2 and EFS, with no involvement of the Rho-kinase signaling pathway. This bladder dysfunction may contribute to the increased risk of urinary tract infections observed in SCD patients. Further studies are necessary to better understand the relationship between DSM reactivity alterations and genitourinary manifestations in SCD. Disclosures: No relevant conflicts of interest to declare.


2020 ◽  
Vol 9 (5) ◽  
pp. 1531
Author(s):  
Nehal Patel ◽  
Ahmad Farooqi ◽  
Michael Callaghan ◽  
Usha Sethuraman

Sickle cell disease (SCD) patients are thought to be at higher risk for urinary tract infections (UTIs) compared to the general population secondary to increased sickling, abnormal urinary acidification, and an inability to concentrate the urine. The incidence of UTI in febrile children with SCD in the United States is unknown. Our objectives were to determine the rate of UTI among febrile SCD children and describe the risk factors for UTI in this population. We conducted a retrospective chart review of all febrile SCD patients <4 years of age who presented to a pediatric emergency department from 2012–2017 and who had a sterile sample of urine for analysis. A total of 167 febrile patients with SCD with 464 visits were identified. The majority were African American (95.2%), female (58.7%), and had hemoglobin SS (HbSS) (65.3%). The rate of UTI was 4.1%. All patients with a UTI were African American females with a median age of 19 months (IQR 12–30). On regression analysis, no risk factors were associated with a UTI. We found the rate of UTI in febrile young children with SCD was comparable to non-SCD children. Larger studies are required to identify the presence of risk factors for UTI in this population.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 2499-2499
Author(s):  
Graham Ellis ◽  
Godwin Chipoka ◽  
Pilirani Mafunga ◽  
Jonathan Brett Heimlich ◽  
Tisungane Mvalo ◽  
...  

Abstract Introduction: The global distribution of sickle cell disease (SCD) overlaps with that of food scarcity and nutritional deficiencies. Chronic anemia secondary to SCD contributes to nutritional deficiencies, for example folic acid. Few studies have evaluated associations between malnutrition and SCD, nor effects of malnutrition on SCD outcomes. Moreover,hydroxyurea(HU), a disease modifying agent for SCD, has not been specifically evaluated in malnourished children although it is known to bind pharmacologically to human serum albumin. Methods: We conducted a cross-sectional nutritional assessment of children receiving chronic SCD care at a referral hospital in the capital city of Malawi, Lilongwe, between January and June 2016. Participants were measured for height, weight, and mid-upper arm circumference. Z-scores and percentiles for anthropomorphic indices were calculated using WHOAnthroSoftware. Nutritional measures of interest were BMI-for-age Z-score to assess wasting and height-for-age Z-score to assess stunting. We examined associations between nutritional status and clinical and laboratory data collected longitudinally at six-month intervals during routine care. Differences based on HU use were examined. Results: Fourteen of 99 (14.1%) participants had moderate-to-severe wasting and 36 of 101 (35.6%) moderate-to-severe stunting. The wasted group was significantly older than the non-wasted group but there was no significant difference in age between the stunted and non-stunted groups (Table 1). We observed significantly lower white blood cell (WBC) and lymphocyte counts in the wasted group when compared to the non-wasted group. The stunted group had significantly lower hemoglobin (Hb) than the non-stunted group. There was also a significantly higher prevalence of fevers in the stunted group than the non-stunted group. Forty-four of 151 (29.1%) participants were receiving HU for a median duration of 126 days (IQR 29 - 196 days). There were no significant differences in age or sex between the HU group and the non-HU group. We observed significantly lower Hb in the HU group when compared to the non-HU group, as expected as HU is typically prescribed for children with more severe SCD in Lilongwe. We also observed higher WBC, absolute neutrophil (ANC), and lymphocyte counts in the HU group. Again reflecting greater SCD severity, we observed a significantly more frequent history of fevers, upper respiratory tract infections, and splenomegaly in the HU group. There were no significant differences in the proportions of wasted participants by HU status [5/33 (15.2%) HUvs20/68 (29.4%) non-HU, p=0.84], and a trend toward more frequent stunting among HU users again likely reflecting growth effects of greater chronic SCD severity [16/33 (48.5%) HUvs9/66 (13.6%) non-HU, p=0.061]. Among HU users, peripheral blood counts were not significantly different in wastedvsnon-wasted children, nor stuntedvsnon-stunted children (Table 2). Conclusion: In a pediatric SCD cohort in Malawi we observed 14.1% of children with significant wasting and 35.6% with significant stunting, highlighting growth effects of chronic illness in this population even among children receiving regular SCD care. Among children prescribed HU, nutritional status did not seem to be associated with HU tolerability. Notably, HU was not associated with significantmyelosuppressionin our cohort including those children with wasting or stunting. More studies are needed to clarify interactions between nutritional status, SCD, and HU, but our data suggests wasting or stunting should not be contraindications to HU use when indicated for pediatric SCD in sub-Saharan Africa. Table 1 Table 1. Table 2 Table 2. Disclosures No relevant conflicts of interest to declare.


2021 ◽  
Vol 21 (2) ◽  
pp. 163-172
Author(s):  
Christèle Nguepou Tchopba ◽  
Gnatoulma Katawa ◽  
Essohana Padaro ◽  
Pélagie Edlom Tchadié ◽  
Simplice Damintoti Karou ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document